![]()
- Shift Into High-Quality Stocks Could Move Market Higher
- China: Low US Interest Rates Threaten Recovery
- Drug Study Questions Effectiveness of Merck's Drugs
- Military Arms Race Dominates Dubai Air Show
- Disaster Film '2012' Drowns Rivals at Box Office
- Cramer: 5 Earnings Reports to Watch Next Week
- Hedge Fund Billionaire Paulson Reports New Citi Stake
- Cities With the Most Home Price Reductions
- This Year's Biggest Thanksgiving Leftover: Cash
- U.S. Stocks Rally for the Second Straight Week
- Dollar is Not Plunging—So 'Calm Down': Market Strategist
- Strategists Say Markets Have More Upside — But How Much?
- Hirschhorn: Risk-Averse Traders
- Roginsky: A Funny Thing Happened on the Way to Financial Reform
- This Year's Biggest Thanksgiving Leftover: Cash
- TV Series Inks Unique Deal For Fight
- First Time Buyers Rescue Housing: Realtors
- Dollar General Trades Higher After Its IPO
MOST SHARED
- CNBC Video: Warren Buffett & Bill Gates - Keeping American Great
- CNBC TRANSCRIPT: Warren Buffett & Bill Gates - Keeping America Great
- Analysis: APEC Nations Back Face-Saving Climate Plan
- Has Twitter's Finest Hours (Seconds) Come and Gone?
- Should China Be Forced to Free-float the Yuan?
- Microsoft's Bill Gates Praises Apple's Steve Jobs For 'Saving the Company'
- Texas Man Drives Bugatti Into Pond; Blames Bird
- Dipping Into Green Investing
Merck said Tuesday it plans to begin late-stage trials next year on a drug to raise "good" HDL cholesterol that has not been dogged by the problems that sank a similar high-profile drug being developed by Pfizer.
![]() |
Torcetrapib, which Pfizer had hoped would become a $10 billion product, was scrapped late last year after it was linked to worrisome numbers of deaths in an $800 million late-stage trial -- the most expensive in history.
Merck said its product has had a very favorable safety record through mid-stage trials. "The safety and tolerability profile of anacetrapib was comparable to placebo in clinical studies conducted to date," the drugmaker said in a release.
Merck, which is hosting a meeting at its New Jersey headquarters on Tuesday with hundreds of investors and industry analysts, said it plans to file for approvals for seven drugs in the next five years.
It will seek U.S. approval next year for MK-524b -- which combines Merck's older Zocor cholesterol fighter with a niacin-based drug called Cordaptive that raises HDL cholesterol -- and an obesity drug called taranabant.
Taranabant, like Sanofi-Aventis' drug rimonabant, blocks the so-called canniboid receptor, the same brain circuit that stimulates hunger in people smoking marijuana. But U.S. regulators earlier this year rejected the Sanofi drug due to its links to depression and suicidal thoughts.
The company plans in 2009 to seek approvals for MK-974, a new type of drug for migraine headaches, and a treatment for acute heart failure called MK-7418 (rolofylline) -- with applications in 2010 for cancer treatment MK-8669 (deforolimus) and a vaccine for hepatitis B called Heplisav.
In 2012, Merck said it will seek U.S. marketing approval for osteoporosis treatment MK-0822 (odanacatib).
Merck on Dec. 4 said 2007 profit would rise 22 percent to 24 percent, due largely to booming sales of newer products, including its Gardasil vaccine against the virus that causes cervical cancer and its year-old oral Januvia treatment for diabetes.
The company's stock has risen 39 percent this year, a top gainer in the Dow Jones industrial average, as Merck seemingly bolted out of its sickbed after two years of anemic profits related to the September 2004 withdrawal of its $2.5 billion-a-year Vioxx arthritis drug.
Merck is hoping to retire thousands of Vioxx product-liability lawsuits with a $4.85 billion settlement reached last month with plaintiffs' lawyers.
Although the drugmaker has projected only a 4.5 percent to 10 percent rise in 2008 earnings, many analysts expect Merck to raise its forecast during the year, as it has done repeatedly in 2007.
Wall Street remains optimistic about Merck's prospects even though the patent expires next year on its $3.1 billion osteoporosis drug Fosamax, and Gardasil faces potential competition from GlaxoSmithKline Plc's Cervarix, a cervical cancer vaccine that is available in Europe but not yet approved in the United States.
Merck's shares slipped 34 cents, or .50 percent, to $60.43 on the New York Stock Exchange amid a slight decline for the drug sector.
- Warren Buffett and Bill Gates spoke to Columbia students, and Buffett made the students a startling offer.
- For the chief of cable company Comcast, growth has been about making deals – generally very large deals.
- Some companies may start using insurance to shift carbon risk from their balance sheets to maybe... yours?
- The president and founder of Genesis Today wants to improve America’s health, and thinks Wal-Mart can help.
- Switzerland's privacy watchdog is taking legal action to force Google to make changes to its Street View service.
- A wealthy, distracted Texas driver crashed his million-dollar Bugatti Veyron sports car into a salt marsh, say police.














